Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotoxicity in preclinical models.
Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma

Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma

A multi-center study demonstrates that preoperative ctDNA detection significantly outperforms traditional clinical criteria in predicting nodal upstaging and survival outcomes for patients with clinical stage I/II ESCC, potentially redefining neoadjuvant treatment strategies.
Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchitis, offering a more precise tool for diagnosing and tracking muco-obstructive lung diseases.
Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting locoregional recurrence and may refine adjuvant treatment decisions for intermediate-risk patients.
Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression, identifying superior combination regimens for specific genomic subgroups.
Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.